Curis Inc (CRIS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.20-5.51%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Curis focuses on advancing its emavusertib Phase 2 study in leukemia. The company aims to manage cash runway with PIPE financing, targeting up to $20.2M in proceeds. Analysts expect nearly 49% revenue growth next year. These steps could stabilize operations and unlock value.
Curis is loss-making with worsening net income, down from $19.36M profit to -$24.19M loss. The stock is in a deep selloff with a 61% drop from highs. Nasdaq listing compliance remains a risk. Revenue growth and profitability remain uncertain.
The price sits about 8% above our $4.81 fair value, reflecting analysts' 49% revenue growth expectation. Our view is cautious given the company's losses and recent earnings misses.
Breaks if: PIPE financing falls short of $20M by mid-2027
Use cash on hand and anticipated proceeds from PIPE financing warrant exercises to fund operations into the second half of 2027.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is in early-stage clinical development with no revenue yet, making it a high-risk proposition with potential for significant upside if clinical trials succeed.
The current valuation suggests that the market views CRIS as relatively cheap compared to peers, but there is a notable expectations gap. The stock's pricing reflects a justified valuation despite the ongoing losses and volatility.
Management is focused on advancing clinical trials and managing cash runway through PIPE financing. However, there is an elevated risk of an earnings miss in the near term due to the company's smaller size and recent erratic performance.
The long-term thesis hinges on the outcomes of clinical trials and the ability to maintain compliance with Nasdaq listing rules. Additionally, broader sector performance and economic conditions will significantly impact CRIS's trajectory.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of last 2 quarters. Cash and cash equivalents were $15.0 million at 2026-Q1, with initial PIPE proceeds of $20.2 million received in 2025-Q4 and potential additional $20.2 million from warrant exercises. Operating losses continue, but management expects this funding to support operations into the second half of 2027. The trajectory shows active cash management with PIPE financing as a key runway element.
“Cash and cash equivalents as of March 31, 2026 of $15.0 million plus anticipated proceeds of up to $20.2 million from PIPE warrant exercises.”
“Initial gross proceeds of $20.2 million received in January 2026 and expected additional proceeds from PIPE warrant exercises.”
Breaks if: No meaningful clinical progress or trial delays reported by FY26
Prioritize the Phase 2 combination study of emavusertib in chronic lymphocytic leukemia with zanubrutinib.
Breaks if: Receive delisting notice or fail to regain compliance by end 2027
Ensure compliance with Nasdaq listing rules to avoid delisting.
Breaks if: Revenue growth falls below 30% YoY next 12 months
Over the next 1 to 3 years, CRIS's success will depend on its clinical advancements and market conditions. Not investment advice.